ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI – PEG 20 ANTIBODIES FOR CANCER TREATMENT

ABSTRACT

The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

[Fig. 1C]